⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50138 | 0.81 | — | — | |
| SCHEMBL5382199 | 0.69 | — | — | |
| SCHEMBL50281 | 0.65 | — | — | |
| SCHEMBL6974171 | 0.65 | — | — | |
| SCHEMBL22100500 | 0.45 | — | — | |
| SCHEMBL486887 | 0.41 | — | — | |
| SCHEMBL10864224 | 0.41 | — | — | |
| SCHEMBL8625019 | 0.41 | — | — | |
| SCHEMBL3092227 | 0.36 | — | — | |
| SCHEMBL29525891 | 0.35 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100540537-C | GFAT inhibitors | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| CN-1882329-A | 4-(1-benzofuran-3-yl-methylideneaminoxy.propoxy))-benzoic acid derivatives and related compounds as PAI-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombosis | WYETH CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| US-7141592-B2 | Substituted oxadiazolidinediones | WYETH (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1680107-A1 | SUBSTITUTED OXADIAZOLIDINEDIONES ALS PAI-1 INHIBITORS | Wyeth (US) | 2006-07-19 | — | — | EP | disclosed |
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1791581-A | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | disclosed |
| EP-1667676-A1 | 4-(1-BENZOFURAN-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1631551-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| US-20050215626-A1 | Substituted benzofuran oximes; inhibiting PAI-1 activity; Plasminogen Activator Inhibitor (PAI); treating thrombosis, pulmonary fibrosis, stroke, myocardial ischemia, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, Alzheimer's disease, renal fibrosis, or cancer | WYETH (US) | 2005-09-29 | — | — | US | disclosed |
| US-20050113428-A1 | Substituted oxadiazolidinediones | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005030199-A1 | 4-(1-BENZOFURAN-3-YL-METHYLIDENEAMINOXY.PROPOXY))-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030203-A1 | SUBSTITUTED OXADIAZOLIDINEDIONES ALS PAI-1 INHIBITORS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004101528-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| EP-0934935-A1 | Heterocyclic substituted phenyl compounds, process and intermediates for their preparation and their use as fungicides and pesticides | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999020615-A2 | PESTICIDE SUBSTITUTED PHENYL CARBAMATES, METHODS AND INTERMEDIATE PRODUCTS FOR PRODUCING THEM, AND USE OF THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-29 | — | — | WO | disclosed |